Duch P, Diaz-Valdivia N, Gabasa M, Ikemori R, et al. Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma. Cancer Sci 2024;115:1505-1519.
PMID: 38476010